Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.

[1]  Qiu-lin Tang,et al.  Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. , 2019, Cancer letters.

[2]  G. Mills,et al.  Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness , 2019, Molecular Cancer Therapeutics.

[3]  M. Hidalgo,et al.  A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours , 2018, British Journal of Cancer.

[4]  Ka-Kui Chan,et al.  Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma , 2018, International journal of cancer.

[5]  N. Hagiwara,et al.  Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. , 2018, Cancer letters.

[6]  R. Bernards,et al.  ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors , 2018, Oncogene.

[7]  R. Bernards,et al.  Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma , 2018, Clinical Cancer Research.

[8]  Ka-Kui Chan,et al.  Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. , 2018, International journal of cancer.

[9]  Steven B. Neuhauser,et al.  PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. , 2017, Cancer research.

[10]  R. Burger,et al.  An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. , 2017, Gynecologic oncology.

[11]  J. Tabernero,et al.  A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer , 2017, Targeted Oncology.

[12]  Y. Okuno,et al.  Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. , 2017, The American journal of pathology.

[13]  G. Mills,et al.  Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response , 2017, Nature Communications.

[14]  H. Watari,et al.  Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma , 2017, British Journal of Cancer.

[15]  Ali Bashashati,et al.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.

[16]  L. Poulain,et al.  The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737 , 2016, Molecular Cancer Therapeutics.

[17]  J. Grilley-Olson,et al.  A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.

[18]  Craig B. Davis,et al.  A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. , 2016, Gynecologic oncology.

[19]  Tomohiko Fukuda,et al.  Title Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging , 2018 .

[20]  K. Russell,et al.  Molecular Profiling of Clear Cell Ovarian Cancers , 2016, International Journal of Gynecologic Cancer.

[21]  D. Gómez-Almaguer,et al.  Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure , 2016, Hematology.

[22]  S. Libutti,et al.  A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. , 2016, Anticancer research.

[23]  A. V. D. Van Der Zee,et al.  Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods , 2015, Scientific Reports.

[24]  H. Kuramoto,et al.  Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. , 2015, Gynecologic oncology.

[25]  C. Lefebvre,et al.  Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. , 2015, Cancer cell.

[26]  James S. Duncan,et al.  Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.

[27]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[28]  N. Yanaihara,et al.  Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma , 2015, PloS one.

[29]  H. Soares,et al.  Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance , 2014, Molecular Cancer Therapeutics.

[30]  J. Kigawa,et al.  The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. , 2014, Oncology reports.

[31]  G. Scambia,et al.  Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma , 2014, Virchows Archiv.

[32]  K. Yamaguchi,et al.  Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway , 2014, Molecular Cancer Therapeutics.

[33]  Weiliang Shi,et al.  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[34]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[35]  D. Bowtell,et al.  Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. , 2013, European journal of cancer.

[36]  Khin Thway,et al.  Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo , 2013, Clinical Cancer Research.

[37]  S. Kaye,et al.  New perspectives on molecular targeted therapy in ovarian clear cell carcinoma , 2013, British Journal of Cancer.

[38]  M. Dimon,et al.  Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo , 2013, Proceedings of the National Academy of Sciences.

[39]  I. Shih,et al.  Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. , 2012, Human pathology.

[40]  Andrew K Godwin,et al.  A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. , 2012, Gynecologic oncology.

[41]  R. Bernards,et al.  Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition , 2012, Leukemia & lymphoma.

[42]  F. Sinicrope,et al.  Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced Cell Death through Autophagy Induction and Down-regulation of p62/Sequestosome 1* , 2011, The Journal of Biological Chemistry.

[43]  A. Ashworth,et al.  Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas , 2011, Clinical Cancer Research.

[44]  Helen X. Chen,et al.  Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. , 2010, Gynecologic oncology.

[45]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[46]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[47]  Q. She,et al.  4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.

[48]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[49]  C. Ng,et al.  Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies , 2009, Clinical Cancer Research.

[50]  P. Workman,et al.  Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 , 2009, Molecular Cancer Therapeutics.

[51]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[52]  S. Steinberg,et al.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer , 2007, Cancer.

[53]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[54]  R. Berkowitz,et al.  PTEN expression in clear cell adenocarcinoma of the ovary. , 2006, Gynecologic oncology.

[55]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[56]  Huajun Yan,et al.  Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.

[57]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[58]  J. Kigawa,et al.  The PI 3 K / mTOR dual inhibitor NVP-BEZ 235 reduces the growth of ovarian clear cell carcinoma , 2022 .